The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score.
ARDS
COVID-19
ICU
Milano Policlinico
ONCOVID-ICU
SOFA score
cancer
invasive ventilation
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
19 03 2021
19 03 2021
Historique:
received:
06
02
2021
revised:
03
03
2021
accepted:
17
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
Over the last months, as oncology specialists, we have frequently been contacted for estimating prognosis for cancer patients affected by COVID-19 infection. Until now, there have been no clear markers to guide decision making regarding the appropriateness of invasive ventilation in cancer patients affected by COVID-19 infection. We developed a practical tool encompassing a prognostic score, "The Milano Policlinico ONCOVID-ICU score." The score is composed of three groups of variables: patient's characteristics such as sex, age, BMI, and comorbidities; oncological variables (treatment intent, life expectancy, on or off-treatment status); and clinical parameters in association with laboratory values (the Sequential Organ Failure Assessment (SOFA) score and D-dimer). The SOFA score includes six different clinical parameters and during the first few days of ICU admissions has an important prognostic role. The oncological history should never represent, per se, a contraindication to intensive care and must be considered together with other variables, such as laboratory values, clinical parameters, and patient characteristics, in order to make the hardest but best possible choice. To our knowledge, "The Milano Policlinico ONCOVID-ICU score" is the first prognostic score proposed in this setting of patients and requires further validation. This tool may be useful to assess the prognosis of cancer patients in critical conditions.
Identifiants
pubmed: 33808623
pii: v13030508
doi: 10.3390/v13030508
pmc: PMC8003474
pii:
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
ID : Italian fiscal contribution "5 x 1000" 2016
Références
Lancet Oncol. 2018 Jun;19(6):e305-e316
pubmed: 29893262
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
ESMO Open. 2016 Sep 13;1(5):e000018
pubmed: 27843637
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Crit Care. 2019 Apr;50:87-91
pubmed: 30502688
Crit Care. 2009;13(1):R15
pubmed: 19200368
Cancer Discov. 2020 Jun;10(6):OF1
pubmed: 32312714
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Crit Care Med. 2007 Mar;35(3):808-14
pubmed: 17235261
Cancer Discov. 2021 Feb 26;:
pubmed: 33637485
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Anesthesiology. 2020 Jun;132(6):1317-1332
pubmed: 32195705